Pub Date : 2019-05-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.03.012
Hui Chen
Aplastic anemia (AA) is considered as an immune-mediated bone marrow failure syndrome, characterized by peripheral pancytopenia and destruction of hematopoietic stem/progenitor cells. Acquired aplastic anemia (aAA) is more common in clinic. Abnormal immunity is one of the major factors mediating the pathogenesis of aAA. This review discusses the current understanding of the immunobiology in aAA, so as to clarify the immune mechanism of this disease, and to provide a theoretical basis for the clinical treatment of aAA. Key words: Anemia, aplastic; Immunity; Immunosuppressive agent; Children; Acquired aplastic anemia
{"title":"Research progress of abnormal immunologic mechanism in acquired aplastic anemia","authors":"Hui Chen","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.012","url":null,"abstract":"Aplastic anemia (AA) is considered as an immune-mediated bone marrow failure syndrome, characterized by peripheral pancytopenia and destruction of hematopoietic stem/progenitor cells. Acquired aplastic anemia (aAA) is more common in clinic. Abnormal immunity is one of the major factors mediating the pathogenesis of aAA. This review discusses the current understanding of the immunobiology in aAA, so as to clarify the immune mechanism of this disease, and to provide a theoretical basis for the clinical treatment of aAA. \u0000 \u0000 \u0000Key words: \u0000Anemia, aplastic; Immunity; Immunosuppressive agent; Children; Acquired aplastic anemia","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"244-248"},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44930786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.03.010
Xiaoli Huang, Sanbin Wang, Lin Liu, L. Luo, Zhongtao Yuan
Graft versus host disease (GVHD) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and is one of the leading causes of death in patients after allo-HSCT. Currently, the classic GVHD prevention regimens are calcineurin inhibitor represented by cyclosporine and tacrolimus in combination with methotrexate or mycophenolate mofetil.The first-line standard regimen for GVHD is based on glucocorticoids. However, this regimen is only effective for some patients, and with a long course of treatment and many adverse reactions, and the patients are easy to be infected. Recent researches show that Janus kinase (JAK) 1/2 inhibitor ruxolitinib has evident clinic efficacy in preventing and treating GVHD with rapid initial effect and less adverse reactions. This article summarizes the basic and clinical researches about ruxolitinib in preventing and treating GVHD, and aims to explore new regimens for preventing and treating GVHD. Key words: Graft vs host disease; Janus kinases; Janus kinase 1; Janus kinase 2; Hematopoietic stem cell transplantation; Adverse effects; Ruxolitinib
{"title":"Research progress of Janus kinase 1/2 inhibitor ruxolitinib in preventing and treating graft versus host disease","authors":"Xiaoli Huang, Sanbin Wang, Lin Liu, L. Luo, Zhongtao Yuan","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.010","url":null,"abstract":"Graft versus host disease (GVHD) is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and is one of the leading causes of death in patients after allo-HSCT. Currently, the classic GVHD prevention regimens are calcineurin inhibitor represented by cyclosporine and tacrolimus in combination with methotrexate or mycophenolate mofetil.The first-line standard regimen for GVHD is based on glucocorticoids. However, this regimen is only effective for some patients, and with a long course of treatment and many adverse reactions, and the patients are easy to be infected. Recent researches show that Janus kinase (JAK) 1/2 inhibitor ruxolitinib has evident clinic efficacy in preventing and treating GVHD with rapid initial effect and less adverse reactions. This article summarizes the basic and clinical researches about ruxolitinib in preventing and treating GVHD, and aims to explore new regimens for preventing and treating GVHD. \u0000 \u0000 \u0000Key words: \u0000Graft vs host disease; Janus kinases; Janus kinase 1; Janus kinase 2; Hematopoietic stem cell transplantation; Adverse effects; Ruxolitinib","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"233-237"},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45586798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.03.004
Ying Zhao, Jianying Yang
Objective To analyze the causes of unqualification in primary blood screening among voluntary blood donors of apheresis platelets in Chengdu Blood Center. Methods A total of 36 127 cases of voluntary blood donors who participated in apheresis platelets donation in Chengdu Blood Center from January to December 2017 were selected as study objects. Age of blood donors was (32.4±7.7) years. Male and female blood donors were 26 423 and 9 704 cases, respectively. Before donation of apheresis platelets, about 4 mL of whole blood was taken from the elbow vein of each blood donor, and these whole blood samples were used for the inspection of primary blood screening. Inspection items of primary blood screening included alanine transaminase (ALT) value, platelet count, hematocrit (HCT), white blood cell count (WBC), hemoglobin (Hb) value, chylemia and hepatitis B virus surface antigen (HBsAg) expression. Then, qualification situations for primary blood screening of apheresis platelets donors were assessed according to Technical Operation Procedure for Blood Stations (2015 Edition). Total unqualified rate of primary blood screening in all apheresis platelets donors, and unqualified rates of each inspection item were counted, respectively. Chi-square test was used to compare the unqualified rates of each inspection item of all blood donors, as well as the unqualified rates between the male and female blood donors. The procedures followed in this study were in line with the requirements of the revised Declaration of Helsinki of World Medical Association in 2013. And all blood donors signed Informed Consent of Blood Donors before blood donating. Results ① In this study, among the 36 127 blood donors who participated in apheresis platelets donation in Chengdu Blood Center in 2017, 19 323 cases were unqualified in primary blood screening, and the total unqualified rate of primary blood screening was 53.49%. ② Among the 19 323 cases of apheresis platelets donors who were unqualified in primary blood screening, the unqualified rates of the primary blood screening items from high to low were 15.82% in unqualification of HCT, 15.45% in unqualification of platelet count, 9.72% in unqualification of ALT value, 7.60% in unqualification of WBC, 3.96% in unqualification of chylemia, 0.80% in unqualification of Hb value, and 0.17% in unqualification of HBsAg. Overall comparison of the unqualified rates of each inspection item of primary blood screening, the difference was statistically significant (χ2=12 724.350, P<0.001). The main causes of unqualification in primary blood screening among apheresis platelets donors were decrease of HCT, increase of ALT value, and decrease of platelet count. The proportion of unqualified blood donors with these three causes accounted for 76.63%(14 806/19 323) of the total unqualified blood donors. ③ Among the 19 323 cases of apheresis platelets donors who were unqualified in primary blood screening, the unqualified rate of mal
{"title":"Analysis of causes of unqualification in primary blood screening among voluntary blood donors of apheresis platelets in Chengdu","authors":"Ying Zhao, Jianying Yang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.004","url":null,"abstract":"Objective \u0000To analyze the causes of unqualification in primary blood screening among voluntary blood donors of apheresis platelets in Chengdu Blood Center. \u0000 \u0000 \u0000Methods \u0000A total of 36 127 cases of voluntary blood donors who participated in apheresis platelets donation in Chengdu Blood Center from January to December 2017 were selected as study objects. Age of blood donors was (32.4±7.7) years. Male and female blood donors were 26 423 and 9 704 cases, respectively. Before donation of apheresis platelets, about 4 mL of whole blood was taken from the elbow vein of each blood donor, and these whole blood samples were used for the inspection of primary blood screening. Inspection items of primary blood screening included alanine transaminase (ALT) value, platelet count, hematocrit (HCT), white blood cell count (WBC), hemoglobin (Hb) value, chylemia and hepatitis B virus surface antigen (HBsAg) expression. Then, qualification situations for primary blood screening of apheresis platelets donors were assessed according to Technical Operation Procedure for Blood Stations (2015 Edition). Total unqualified rate of primary blood screening in all apheresis platelets donors, and unqualified rates of each inspection item were counted, respectively. Chi-square test was used to compare the unqualified rates of each inspection item of all blood donors, as well as the unqualified rates between the male and female blood donors. The procedures followed in this study were in line with the requirements of the revised Declaration of Helsinki of World Medical Association in 2013. And all blood donors signed Informed Consent of Blood Donors before blood donating. \u0000 \u0000 \u0000Results \u0000① In this study, among the 36 127 blood donors who participated in apheresis platelets donation in Chengdu Blood Center in 2017, 19 323 cases were unqualified in primary blood screening, and the total unqualified rate of primary blood screening was 53.49%. ② Among the 19 323 cases of apheresis platelets donors who were unqualified in primary blood screening, the unqualified rates of the primary blood screening items from high to low were 15.82% in unqualification of HCT, 15.45% in unqualification of platelet count, 9.72% in unqualification of ALT value, 7.60% in unqualification of WBC, 3.96% in unqualification of chylemia, 0.80% in unqualification of Hb value, and 0.17% in unqualification of HBsAg. Overall comparison of the unqualified rates of each inspection item of primary blood screening, the difference was statistically significant (χ2=12 724.350, P<0.001). The main causes of unqualification in primary blood screening among apheresis platelets donors were decrease of HCT, increase of ALT value, and decrease of platelet count. The proportion of unqualified blood donors with these three causes accounted for 76.63%(14 806/19 323) of the total unqualified blood donors. ③ Among the 19 323 cases of apheresis platelets donors who were unqualified in primary blood screening, the unqualified rate of mal","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"67 1","pages":"201-206"},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69910399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.03.006
Jiasi Zhang
Multiple myeloma (MM) is a plasma cell malignant disease which is characterized by unlimited proliferation of monoclonal plasma cells and multiple infiltration of the bone marrow. Extramedullary myeloma (EMM) is found in some MM patients with extramedullary disease (EMD) at the initial diagnosis or during treatment. Particularly the hematogenous EMM has great heterogeneity and possesses poor prognosis in clinical applications. In general, the mechanism of EMM is closely related to cytogenetic abnormalities, the changes of the adhesion molecules, chemokine receptors, abnormal cytokine expression and exosomes etc. in bone marrow microenvironment. The authors focuses on the pathogenesis of EMM, in order to explore the causes of EMM heterogeneity. Key words: Multiple myeloma; Neoplasm metastasis; Plasmacytoma; Extramedullary myeloma; Hematogenous metastasis; Pathogenesis
{"title":"Research progresses in the pathogenesis of multiple myeloma with extramedullary disease","authors":"Jiasi Zhang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.006","url":null,"abstract":"Multiple myeloma (MM) is a plasma cell malignant disease which is characterized by unlimited proliferation of monoclonal plasma cells and multiple infiltration of the bone marrow. Extramedullary myeloma (EMM) is found in some MM patients with extramedullary disease (EMD) at the initial diagnosis or during treatment. Particularly the hematogenous EMM has great heterogeneity and possesses poor prognosis in clinical applications. In general, the mechanism of EMM is closely related to cytogenetic abnormalities, the changes of the adhesion molecules, chemokine receptors, abnormal cytokine expression and exosomes etc. in bone marrow microenvironment. The authors focuses on the pathogenesis of EMM, in order to explore the causes of EMM heterogeneity. \u0000 \u0000 \u0000Key words: \u0000Multiple myeloma; Neoplasm metastasis; Plasmacytoma; Extramedullary myeloma; Hematogenous metastasis; Pathogenesis","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"212-217"},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45917892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.03.017
Yang Wang
Autophagy is one of hotspots in the biomedical field. It has been shown that autophagy is related to the pathogenesis of various diseases. The autophagic flux is a process from the formation of the barrier membrane to the autolysis of the lysosome to complete the hydrolysis function, which is a complete, multistep and dynamic autophagy process. Therefore, autophagic flux can be used as a measure of autophagy level, and qualitative and quantitative detection of autophagic flux can be achieved by combining experimental methods of dynamic and static. It can reflect the level of autophagy more accurately and objectively. This article intends to give a brief introduction to the detection of autophagy, and especially describes various detection methods of autophagic flux, in order to provide technical support for the majority of related researchers. Key words: Autophagy; Clinical laboratory techniques; Microscopy, electron; Microscopy, fluorescence; Biological markers; Plasmids; Autophagy flux
{"title":"Research progress on autophagy detection","authors":"Yang Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.017","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.017","url":null,"abstract":"Autophagy is one of hotspots in the biomedical field. It has been shown that autophagy is related to the pathogenesis of various diseases. The autophagic flux is a process from the formation of the barrier membrane to the autolysis of the lysosome to complete the hydrolysis function, which is a complete, multistep and dynamic autophagy process. Therefore, autophagic flux can be used as a measure of autophagy level, and qualitative and quantitative detection of autophagic flux can be achieved by combining experimental methods of dynamic and static. It can reflect the level of autophagy more accurately and objectively. This article intends to give a brief introduction to the detection of autophagy, and especially describes various detection methods of autophagic flux, in order to provide technical support for the majority of related researchers. \u0000 \u0000 \u0000Key words: \u0000Autophagy; Clinical laboratory techniques; Microscopy, electron; Microscopy, fluorescence; Biological markers; Plasmids; Autophagy flux","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"268-272"},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42074776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.03.003
Yanhong Liu, Heming Zhu
Objective To explore the influences of seasonal recruitment mode of voluntary blood donation on blood collection and supply of whole blood and erythrocyte components. Methods A total of 239 949 voluntary blood donors who participated in whole blood and erythrocyte components donation during January 2013 to December 2018 in Binzhou Blood Center were chosen as subjects. There were 165 564 male donors and 74 385 female donors in the subjects, whose age ranged from 18 to 55 years. The Qiao Information Management System v9.0 (Tangshan Qiao Technology Co., Ltd.) was used to collect all the blood donation data of 239 949 blood donors in this study, such as the time of participating in blood donation, the mode of blood donation, the amount of blood collection and supply of whole blood and erythrocyte components. The blood collection amount of whole blood and erythrocyte components, the seasonal ratio of blood collection, the blood supply amount of whole blood and erythrocyte components, the seasonal ratio of blood supply, as well as the difference between seasonal ratios of blood collection and blood supply in Binzhou Blood Center in each season from 2013 to 2018 , were calculated respectively. The total blood collection and supply amount of whole blood and erythrocyte components in Binzhou Blood Center in four seasons from 2013 to 2018 were compared by variance analysis, and the least significant difference (LSD) method was used for comparison between two seasons. The procedures followed in this study were in line with the requirements of the revised Helsinki Declaration of the World Medical Association in 2013. Before blood donation, all the blood donors signed the Informed Consent of Blood Donors. Results ① In this study, the seasonal ratios of blood collection of whole blood and erythrocyte components of Binzhou Blood Center in the spring, summer, autumn and winter from 2013 to 2018 were 95.8%, 93.8%, 113.4% and 97.0%, respectively. Among them, the seasonal ratios of group blood collection were 39.9%, 56.7%, 190.3% and 113.2%, respectively; the seasonal ratios of street blood collection was 117.9%, 108.5%, 83.1% and 90.6%, respectively. In spring, summer, autumn and winter form 2013 to 2018, the blood collection amount of whole blood and erythrocyte components of Binzhou Blood Center were (15 877.0±924.3) U, (15 548.2±1 105.3) U, (18 790.8±1 057.7) U and (16 065.7±1 062.3) U, respectively. There was a statistically significant difference in blood collection amount among four seasons (F=12.418, P 0.05). ③ The difference of seasonal ratios between the total blood collection and supply of whole blood and erythrocyte components of Binzhou Blood Center in spring, summer, autumn and winter from 2013 to 2018 were -5.9%, -3.0%, 13.8% and -4.9%, respectively. Only the blood collection in autumn could meet the supply requirements, and there were shortages in other three seasons. Conclusions In recent years, there are seasonal insufficiency o
{"title":"Influences of seasonal recruitment mode of voluntary blood donors on blood collection and supply of whole blood and erythrocyte components","authors":"Yanhong Liu, Heming Zhu","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.003","url":null,"abstract":"Objective \u0000To explore the influences of seasonal recruitment mode of voluntary blood donation on blood collection and supply of whole blood and erythrocyte components. \u0000 \u0000 \u0000Methods \u0000A total of 239 949 voluntary blood donors who participated in whole blood and erythrocyte components donation during January 2013 to December 2018 in Binzhou Blood Center were chosen as subjects. There were 165 564 male donors and 74 385 female donors in the subjects, whose age ranged from 18 to 55 years. The Qiao Information Management System v9.0 (Tangshan Qiao Technology Co., Ltd.) was used to collect all the blood donation data of 239 949 blood donors in this study, such as the time of participating in blood donation, the mode of blood donation, the amount of blood collection and supply of whole blood and erythrocyte components. The blood collection amount of whole blood and erythrocyte components, the seasonal ratio of blood collection, the blood supply amount of whole blood and erythrocyte components, the seasonal ratio of blood supply, as well as the difference between seasonal ratios of blood collection and blood supply in Binzhou Blood Center in each season from 2013 to 2018 , were calculated respectively. The total blood collection and supply amount of whole blood and erythrocyte components in Binzhou Blood Center in four seasons from 2013 to 2018 were compared by variance analysis, and the least significant difference (LSD) method was used for comparison between two seasons. The procedures followed in this study were in line with the requirements of the revised Helsinki Declaration of the World Medical Association in 2013. Before blood donation, all the blood donors signed the Informed Consent of Blood Donors. \u0000 \u0000 \u0000Results \u0000① In this study, the seasonal ratios of blood collection of whole blood and erythrocyte components of Binzhou Blood Center in the spring, summer, autumn and winter from 2013 to 2018 were 95.8%, 93.8%, 113.4% and 97.0%, respectively. Among them, the seasonal ratios of group blood collection were 39.9%, 56.7%, 190.3% and 113.2%, respectively; the seasonal ratios of street blood collection was 117.9%, 108.5%, 83.1% and 90.6%, respectively. In spring, summer, autumn and winter form 2013 to 2018, the blood collection amount of whole blood and erythrocyte components of Binzhou Blood Center were (15 877.0±924.3) U, (15 548.2±1 105.3) U, (18 790.8±1 057.7) U and (16 065.7±1 062.3) U, respectively. There was a statistically significant difference in blood collection amount among four seasons (F=12.418, P 0.05). ③ The difference of seasonal ratios between the total blood collection and supply of whole blood and erythrocyte components of Binzhou Blood Center in spring, summer, autumn and winter from 2013 to 2018 were -5.9%, -3.0%, 13.8% and -4.9%, respectively. Only the blood collection in autumn could meet the supply requirements, and there were shortages in other three seasons. \u0000 \u0000 \u0000Conclusions \u0000In recent years, there are seasonal insufficiency o","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"194-200"},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48908575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.03.016
P. Dong
Recent genomic studies have revealed the existence of many somatic gene mutations associated with hematologic malignancies. These somatic mutations drive the expansion from a single cell to a detectable hematopoietic clone. Clonal hematopoiesis (CH) is age-associated and related to increased risk of hematologic malignancy. Thrombopoietin (TPO) stimulates megakaryocytogenesis, platelet activation and hematopoietic stem cell(HSC) maintenance after combining with c-MPL on cell surface. Increasing researches have revealed the relationship between the level of TPO and CH. This article reviews the reasearch progress in the relationship between level of TPO and CH, in order to provide evidences for clinical prevention, diagnosis and treatment of hematologic malignancies. Key words: Thrombopoietin; Hematopoiesis; Mutation; Hematologic neoplasms; Clonal evolution; MPL protein, human
{"title":"Research progress in relationship between level of thrombopoietin and clonal hematopoiesis","authors":"P. Dong","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.016","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.016","url":null,"abstract":"Recent genomic studies have revealed the existence of many somatic gene mutations associated with hematologic malignancies. These somatic mutations drive the expansion from a single cell to a detectable hematopoietic clone. Clonal hematopoiesis (CH) is age-associated and related to increased risk of hematologic malignancy. Thrombopoietin (TPO) stimulates megakaryocytogenesis, platelet activation and hematopoietic stem cell(HSC) maintenance after combining with c-MPL on cell surface. Increasing researches have revealed the relationship between the level of TPO and CH. This article reviews the reasearch progress in the relationship between level of TPO and CH, in order to provide evidences for clinical prevention, diagnosis and treatment of hematologic malignancies. \u0000 \u0000 \u0000Key words: \u0000Thrombopoietin; Hematopoiesis; Mutation; Hematologic neoplasms; Clonal evolution; MPL protein, human","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"264-267"},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49516098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Heme is not only the coenzyme of hemoglobin(Hb), but also the coenzyme of myoglobin, cytochrome and peroxidase. It plays an important role in oxygen binding, electron transmission and signal transduction. However, free-heme is the metabolite of erythrocyte rupture, which is easy to penetrate the cell membrane and induce oxidative stress injury to tissues and cells. Many studies have found that the pathological processes of many diseases and organ injuries involve the toxic effects of free-heme, including immunity and inflammation, transfusion-related diseases, atherosclerosis, heart, brain, liver and kidney organ damage, etc.. This article reviews the current research progress in the pathological process of free-heme related diseases. Key words: Heme; Hemolysis; Erythrocytes; Oxidative stress; Pathologic processes
{"title":"Advances in pathological researches of free-heme","authors":"Xin Wei, Yaomei Wang, Xiaoli Qu, Jianjun Yang, Wei Zhang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.014","url":null,"abstract":"Heme is not only the coenzyme of hemoglobin(Hb), but also the coenzyme of myoglobin, cytochrome and peroxidase. It plays an important role in oxygen binding, electron transmission and signal transduction. However, free-heme is the metabolite of erythrocyte rupture, which is easy to penetrate the cell membrane and induce oxidative stress injury to tissues and cells. Many studies have found that the pathological processes of many diseases and organ injuries involve the toxic effects of free-heme, including immunity and inflammation, transfusion-related diseases, atherosclerosis, heart, brain, liver and kidney organ damage, etc.. This article reviews the current research progress in the pathological process of free-heme related diseases. \u0000 \u0000 \u0000Key words: \u0000Heme; Hemolysis; Erythrocytes; Oxidative stress; Pathologic processes","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"254-258"},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46341283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.03.001
Zhe Wang
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin′s lymphoma (NHL), DLBCL comprised about 1/3 of all NHL cases. DLBCL is a kind of highly aggressive neoplasm. Precise diagnosis of DLBCL was only made by combination of morphological, immunophenotype and clinical manifestations evidence. In recent decade, molecular study of DLBCL progresses very rapidly, the new advances promoted the prognosis prediction and treatment strategy of DLBCL. In this paper, we will focus on the important pathological issues for the treatment and prognosis prediction of DLBCL, for examples, pathologic subtype, morphology, cell of origin, genetic alteration, immunophenotype and tumor immune micro-enviroment. Key words: Lymphoma, B-cell; Lymphoma, large B-cell, diffuse; Tumor microenviroment; Genetic alteration; Cell of origin
{"title":"Related pathological factors in treatment and prognosis of diffuse large B-cell lymphoma","authors":"Zhe Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.001","url":null,"abstract":"Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin′s lymphoma (NHL), DLBCL comprised about 1/3 of all NHL cases. DLBCL is a kind of highly aggressive neoplasm. Precise diagnosis of DLBCL was only made by combination of morphological, immunophenotype and clinical manifestations evidence. In recent decade, molecular study of DLBCL progresses very rapidly, the new advances promoted the prognosis prediction and treatment strategy of DLBCL. In this paper, we will focus on the important pathological issues for the treatment and prognosis prediction of DLBCL, for examples, pathologic subtype, morphology, cell of origin, genetic alteration, immunophenotype and tumor immune micro-enviroment. \u0000 \u0000 \u0000Key words: \u0000Lymphoma, B-cell; Lymphoma, large B-cell, diffuse; Tumor microenviroment; Genetic alteration; Cell of origin","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"185-188"},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48838294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-20DOI: 10.3760/CMA.J.ISSN.1673-419X.2019.03.005
Lin Zhu, G. Ding, Yong-Bin Liu, Zhi-bing Yang, Anxiu Jiao, Jing-han Liu
Objective To explore the application of cryopreserved platelets without dimethyl sulfoxide (DMSO) elution of blood collection and supply institutions in China. Methods From November to December 2015, a total of 352 blood collection and supply institutions of 31 provinces, autonomous regions and municipalities across China were selected as research subjects by random sampling method. The application of cryopreserved platelets without DMSO elution in the blood collection and supply institutions of this study was investigated by telephone inquiries. The application of cryopreserved platelets without DMSO elution mainly refered to the preparation and clinical release of cryopreserved platelets without DMSO eluction of blood collection and supply institutions. The specific investigation items were as follows: ① the application time of cryopreserved platelets without DMSO elution as of December 2015; ② annual application of cryopreserved platelets without DMSO elution as of December 2015; ③ whether still use cryopreserved platelets without DMSO elution currently; ④ the reasons for discontinuation of cryopreserved platelets without DMSO elution; ⑤ whether cryopreserved platelets without DMSO elution would still be used; ⑥ the transfusion adverse reactions of patients who accepted transfusion of cryopreserved platelets without DMSO elution. Results Among the 352 blood collection and supply institutions of 31 provinces, autonomous regions and municipalities in this study, there were 196 institutions which had used cryopreserved platelets without DMSO elution in the past, accounting for 55.7% (196/352) of all blood collection and supply institutions in the study. As of December 2015, the total application amount of cryopreserved platelets without DMSO elution was 290 377 U in these 196 institutions, with an average application time of 8.3 years, and a maximum application time of 15 years. There was no clinical report of transfusion adverse reactions in patients who transfused cryopreserved platelets without DMSO elution. As of December 2015, a number of 133 blood collection and supply institutions still used cryopreserved platelets without DMSO elution, accounting for 37.8% (133/352) of all institutions surveyed, and accounting 67.9% (133/196) of institutions which had used cryopreserved platelets without DMSO elution previously. Among 196 blood collection and supply institutions which had used cryopreserved platelets without DMSO elution previously, a number of 63 institutions had stopped using cryopreserved platelets without DMSO elution. The reason for discontinuation of application of cryopreserved platelets without DMSO elution was without related national standard. The average application time for cryopreserved platelets without DMSO elution of institutions before discontinuation was 5.1 years. Conclusions In the blood collection and supply institutions nationwide, the application time of cryopreserved platelets without DMSO elutio
{"title":"Investigation on application of cryopreserved platelets without dimethyl sulfoxide elution of blood collection and supply institutions in China","authors":"Lin Zhu, G. Ding, Yong-Bin Liu, Zhi-bing Yang, Anxiu Jiao, Jing-han Liu","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.03.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.03.005","url":null,"abstract":"Objective \u0000To explore the application of cryopreserved platelets without dimethyl sulfoxide (DMSO) elution of blood collection and supply institutions in China. \u0000 \u0000 \u0000Methods \u0000From November to December 2015, a total of 352 blood collection and supply institutions of 31 provinces, autonomous regions and municipalities across China were selected as research subjects by random sampling method. The application of cryopreserved platelets without DMSO elution in the blood collection and supply institutions of this study was investigated by telephone inquiries. The application of cryopreserved platelets without DMSO elution mainly refered to the preparation and clinical release of cryopreserved platelets without DMSO eluction of blood collection and supply institutions. The specific investigation items were as follows: ① the application time of cryopreserved platelets without DMSO elution as of December 2015; ② annual application of cryopreserved platelets without DMSO elution as of December 2015; ③ whether still use cryopreserved platelets without DMSO elution currently; ④ the reasons for discontinuation of cryopreserved platelets without DMSO elution; ⑤ whether cryopreserved platelets without DMSO elution would still be used; ⑥ the transfusion adverse reactions of patients who accepted transfusion of cryopreserved platelets without DMSO elution. \u0000 \u0000 \u0000Results \u0000Among the 352 blood collection and supply institutions of 31 provinces, autonomous regions and municipalities in this study, there were 196 institutions which had used cryopreserved platelets without DMSO elution in the past, accounting for 55.7% (196/352) of all blood collection and supply institutions in the study. As of December 2015, the total application amount of cryopreserved platelets without DMSO elution was 290 377 U in these 196 institutions, with an average application time of 8.3 years, and a maximum application time of 15 years. There was no clinical report of transfusion adverse reactions in patients who transfused cryopreserved platelets without DMSO elution. As of December 2015, a number of 133 blood collection and supply institutions still used cryopreserved platelets without DMSO elution, accounting for 37.8% (133/352) of all institutions surveyed, and accounting 67.9% (133/196) of institutions which had used cryopreserved platelets without DMSO elution previously. Among 196 blood collection and supply institutions which had used cryopreserved platelets without DMSO elution previously, a number of 63 institutions had stopped using cryopreserved platelets without DMSO elution. The reason for discontinuation of application of cryopreserved platelets without DMSO elution was without related national standard. The average application time for cryopreserved platelets without DMSO elution of institutions before discontinuation was 5.1 years. \u0000 \u0000 \u0000Conclusions \u0000In the blood collection and supply institutions nationwide, the application time of cryopreserved platelets without DMSO elutio","PeriodicalId":13774,"journal":{"name":"International Journal of Blood Transfusion and Hematology","volume":"42 1","pages":"207-211"},"PeriodicalIF":0.0,"publicationDate":"2019-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48966962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：